When Sue Wolff is ready to start the journey, she draws the blinds to her windows overlooking Highway 89, converts her office ...

Life Sciences’ shareholders voted to approve the strategic combination with Beckley Psytech Limited and the corporate redomiciliation at the ...

QOL agreed to buy Evoke for $11 a share in a deal expected to close by the end of the year. QOL said it will fund the transaction with cash on hand. Shares of Evoke have more than doubled to $10.70 ...

QOL Medical to Acquire All Outstanding Shares of Evoke for $11.00 Per Share in Cash Represents a 139.7% premium to most recent Nasdaq closing price Transaction expected to close by the end of 2025 ...

An ER doctor reveals that using decongestants for cold symptoms carries risks that land people in the hospital each year.

Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues ...

Illicit drug overdoses and the deaths they cause are trending down this year, despite spikes in a handful of states, ...

Researchers are increasingly developing antibody therapies to treat infectious diseases. Therapies are being designed to reduce the severity of infections such as bird flu, and cure chronic conditions ...

Evoke Pharma (NASDAQ:EVOK) shares surged 134% on Tuesday after the company revealed it had signed a definitive agreement to be acquired by QOL Medical, a privately held biopharmaceutical company ...

Revenues increased 57% for the quarter and 38% for the six months ended September 30, 2025 compared to same periods last yearU.S. revenue increased 115% for the quarter and 86% for the six months ...